Products and Services
RegenMed incorporates one or more of the following products and services in providing its solutions. Click on the any of the below to learn more.
Patient Reported Outcomes
Electronic Data Capture
Peer To Peer Collaboration
Social Media Management
Ethical Industry Intermediation
IRB’s and Ethics Committees
Extracting financial and reputational value from everyday cases begins with a clinical study, tailored to the client’s specific objective. If desired, the study design may be complex, have several end points, involve multiple study centers and contemplate two years or more of longitudinal data. To be efficient, however, it should reflect only those data points and time period needed to achieve the client’s objective.
Internal RegenMed resources, as well as its extensive international network, are available to assist with all elements of the study design. The inCytes™ and Benchmarc™ platforms, when combined with supporting processes, allow implementation with minimum burden and low cost. This allows great flexibility in study design, and incremental study expansion of studies as and when desired.
Longitudinal patient reported outcomes are an important part of many studies. Outcomes can be benchmarked against the patient’s immediate pre-procedure clinical data, against other relevant datasets, the clinician’s treatment plan and/or data obtainable from medical wearables.
RegenMed has a large library of PROMS, and can easily design and implement any other outcomes scoring form desired. To achieve maximum patient compliance, and useful data, we recommend simplicity and avoiding overly subjective or conflicting questions. If desired and authorized, RegenMed can handle patient communications relating to outcomes reporting.
Through its U.S.-patent pending platforms, inCytes™ and Benchmarc™, RegenMed ensures a low-burden, yet clinical-grade execution of even the most complex multi-center studies. Both platforms are “clinical-grade”, and compliant with various legal and technical standards expected in advanced use cases.
They support robust data filtering and export functionality, data access roles and permissions, multi-center trials, easy patient enrollment, excellent clinician and patient user experience, scribe or other Team Member use, SMS messaging, and patient education. They are highly scalable, and customizable at each of the Sponsor, clinician and patient levels.
RegenMed issues releases with new features of value to patients, clinicians and industry approximately every two months.
Substantive yet efficient patient engagement is as important before and after, as it is during, the in-person clinical encounter. This importance is only heightened by telemedicine and medical wearables trends.
RegenMed’s Benchmarc™ platform provides a customized, modern and convenient patient user-experience. The patient can track her progress against her initial clinical data, against clinician-specified goals, against broader benchmarks found in the literature, or against various patient cohorts. The clinicians can set alerts against pre-determined criteria – for example automatically to congratulate the patient on progress, or to suggest a consult.
A powerful inCytes™ feature is its ability to support any number of study collaborators – whether within or across institutional and national boundaries. Each clinician-investigator maintains his customized brand in dealing with his/her patient, without losing the integrity of the study as a whole. All elements of such studies retain their authenticity and auditability.
Similarly, each clinician in a multi-center trial can use variations to the basic study design, without affecting the legitimacy of the data captured against its “root protocol”.
Peer-to-peer collaboration is not only a powerful approach to lower cost multi-center trials. It is also an effective way for clinicians to learn from and otherwise communicate with each other, and develop new standards of care.
Influence in healthcare, as most other areas, is developed and exercised through social media. RegenMed works with clinicians to establish, develop and monetize a social media presence. Much of this can take place on popular platforms such as Twitter, LinkedIn and Facebook. Often, however, these traditional platforms present disadvantages. – too public, uncurated and insufficiently focused content, questionable scientific/medical validity.
The company’s Circle Academies address these challenges, while preserving the power of traditional media channels. Each Academy has a specific clinical/scientific focus. Membership is limited to clinicians with an interest in that focus. Content is curated, with the objective of providing genuine business and clinical value. Members may interact with all other Members, or with select others through private chat. Multimedia content is fully supported. Each Academy has an “Industry Corner”, where manufacturers can offer discounts, training, product information and post requests for study investigators.
Laws, regulations and internal ethical policies define and increasingly limit the nature of interaction between clinicians and industry representatives. This can prevent what otherwise would be valuable collaboration leading to medical advances and better patient care.
Therefore, industry sponsorship of clinical trials, studies and medical education represent particularly important channels for productive interaction. These channels are often intermediated by third parties – medical societies, conference organizers, journal publishers and clinical research organizations for example.
RegenMed is often such a valuable intermediator. The company’s turnkey platforms and processes enable busy clinicians to design and execute trials, studies, trials, patient education materials and productive peer-to-peer collaboration in a low-cost, burden-free manner. Meanwhile, those same tools and processes provide industry with transparent, ethical and valuable channels for supporting clinicians in the delivery of better patient care.
Healthcare is regulated on several levels – patient privacy, technical, audit trails and other. On the one hand, RegenMed’s platforms and processes are designed for low-burden use by busy clinicians. On the other, they are “clinical grade”. inCytes™ (for practitioners), and Benchmarc™ (for patients) are tightly integrated and compliant with HIPAA, GDPR, 21 CFR Part 11 (U.S.), FHIR HL7, local server selection, and documentation requirements.
RegenMed also maintains a full-time team of experienced programmers able to assist in the development of API’s for integration with EMR’s or similar programs.
Benchmarc™ and related RegenMed processes also support clinician partners in obtaining “compliance” by patients with treatment protocols and outcomes reporting.
Studies and trials will often benefit from approvals by institutional or commercial IRB (in the United States) or medical ethics committee (Europe and elsewhere).
The typical use case for RegenMed’s clients involves a clinical/scientific study design (“Observational Protocol”), end-points, customizable consent and other patient enrollment elements, flexible report generation, data exports, full documentation and audit trails.
These elements greatly streamline working with IRB’s and MEC’s. If desired by clinical or industry partners, RegenMed can oversee those interactions.
Interested in Learning More about Circles for Healthcare Practitioners?Talk to an Expert Today
Related Latest News from RegenMed
The Latest features expert opinions, real-world data and other news from our growing community of Circles.
September 7, 2021
Introducing Regenerative Medicine Services of France
Christian Jorgensen, M.D., Ph.D, and Rosanna Feirrera Lopez, M.D., of CHU Montpellier, Loïc Le Coz, M.D., of CosmaGap, and Marion Bertrand-Marchand M.D., of ...
July 14, 2021
PRP vs. Adipose in Knee OA, Argentina
Dr. Viña first selected a pathology (Knee OA) and patient-reported outcomes measure (KOOS + VAS) to begin gathering outcomes data from his patients ...
Contact us to
Explore Our Solutions
One of our specialists will be in touch within 48 hours.